
Compugen Unveils MAIA-Ovarian Trial Design at ESMO Congress
At the ESMO Gynaecological Cancers Congress in Copenhagen, Compugen presented a trial-in-progress poster for the MAIA-ovarian study, an adaptive platform trial testing the anti-PVRIG antibody COM701 as a maintenance therapy for patients suffering from relapsed platinum-sensitive ovarian cancer.





















